CAS 1197-17-7
:acide cis-4-aminométhylcyclohexane-1-carboxylique
- Tranexamic acid cis-form
- cis-AMCHA
- cis-4-(Aminomethyl)cyclohexanecarboxylic acid
- 4-(Aminomethyl)Cyclohexane-1-Carboxylic Acid
- cis-4-Aminomethylcyclohexane-1-carboxylic acid
Cyclohexanecarboxylic acid, 4-(aminomethyl)-, cis-
CAS :Formule :C8H15NO2Degré de pureté :96%Couleur et forme :SolidMasse moléculaire :157.2102cis-4-(Aminomethyl)cyclohexanecarboxylic acid
CAS :cis-4-(Aminomethyl)cyclohexanecarboxylic acidDegré de pureté :98%Masse moléculaire :157.21g/molTranexamic Acid EP Impurity B
CAS :Formule :C8H15NO2Couleur et forme :White To Off-White SolidMasse moléculaire :157.21cis-Tranexamic Acid
CAS :Produit contrôléFormule :C8H15NO2Couleur et forme :White To Light BeigeMasse moléculaire :157.21trans-4-(Aminomethyl)cyclohexanecarboxylic acid
CAS :Trans-4-(aminomethyl)cyclohexanecarboxylic acid (AMCA) is a histamine antagonist that is used to treat bowel disease. It may also be useful for the treatment of other inflammatory diseases and as an anticoagulant. AMCA has been shown to be safe and effective for the prevention of postoperative bleeding in patients who are undergoing major surgery. This drug is a potent inhibitor of platelet aggregation, but does not affect the function of erythrocytes or leukocytes. AMCA inhibits platelet aggregation by blocking the binding of adenosine diphosphate (ADP) to its receptor on platelets, thus inhibiting ADP-mediated activation of phospholipase A2 and arachidonic acid release from membranes. An increase in blood levels of AMCA may lead to cardiac toxicity and bleeding events.
Formule :C8H15NO2Degré de pureté :Min. 95%Masse moléculaire :157.21 g/mol








